Diamyd Medical

Diamyd Medical is a Swedish biopharmaceutical company focused on precision medicine for type 1 diabetes. Its core work centers on developing antigen-specific immunotherapies, led by the investigational product Diamyd® (rhGAD65/alum), alongside in-house manufacturing of the recombinant GAD65 active ingredient in Umeå.

— Diamyd Medical
%
Clinical-stage therapeutics70% Investigational drug candidates and clinical programs for type 1 diabetes.
Biomanufacturing20% Internal production of recombinant GAD65 active pharmaceutical ingredient.
Research and platform development10% Precision medicine research, biomarker strategy, and supporting R&D activities.

Diamyd Medical does not sell a broad commercial product portfolio; its main end users are patients with type 1...

  • Type 1 diabetes patientsprimary

    Patients in clinical studies who receive or are evaluated for Diamyd® to preserve endogenous insulin production.

  • Clinical trial sites and investigatorsprimary

    Hospitals and clinics that administer trials, collect samples, and generate the clinical data needed for approval.

  • Pharmaceutical licensing partnerssecondary

    Potential partners that may license Diamyd® or support commercialization in selected markets.

  • External biomanufacturing customersemerging

    Third parties that may use the Umeå facility for biological compound production.

Diamyd Medical is headquartered in Stockholm and operates a manufacturing facility in Umeå, Sweden...

  • •Headquartered in Stockholm, Sweden
  • •Manufacturing and API production in Umeå, Sweden
  • •DIAGNODE-3 clinical program in the United States and Europe
  • •Patent protection across the US, Europe, Asia, and other markets
  • •Future commercialization depends on selected regional approvals

Diamyd Medical’s strategy is built around advancing Diamyd® through registrational clinical development and using...

01
Complete and read out DIAGNODE-3short-term

The Phase 3 program is the key clinical and regulatory value driver.

02
Build precision-medicine positioningmedium-term

Genetically defined patient selection can improve clinical differentiation and commercial focus.

03
Secure manufacturing and supply controlmedium-term

Owning API production reduces dependence on external suppliers and supports scalability.

04
Protect and extend intellectual propertylong-term

Patent coverage underpins future licensing and commercialization economics.

Diamyd Medical faces the typical risks of a clinical-stage biotech company: trial failure, regulatory setbacks, and...

critical

Drug development failure

The company depends on positive clinical data from DIAGNODE-3 and related studies.

Scope
Diamyd® and the Phase 3 program
Materiality
high
high

Regulatory approval risk

Approval depends on FDA and other authority decisions, which can change timelines or requirements.

Scope
BLA and future market authorization
Materiality
high
high

Intellectual property risk

Patent scope, validity, and enforceability are central to future commercialization and licensing.

Scope
GAD65 and precision medicine patents
Materiality
high
high

Financing risk

Clinical-stage biotech companies often require external capital before revenues are established.

Scope
Ongoing R&D and trial funding
Materiality
high
medium

Manufacturing and supply-chain risk

The company relies on successful scale-up and reliable GMP production of recombinant GAD65.

Scope
Umeå facility and API supply
Materiality
medium
Research and development expense recognition
Timing of DIAGNODE-3 and other studies drives expense volatility
Public funding recognition
Can create uneven recognition across periods
Lease accounting
Affects EBITDA-like measures, leverage, and depreciation/interest split
Share-based compensation
Impacts operating costs and equity dilution
Foreign currency translation
Can affect reported profit and balance sheet values

VIEMED HEALTHCARE, INC.

VMD · Services-Misc Health & Allied Services, NEC

LifeMD, Inc.

LFMD · Services-Offices & Clinics of Doctors of Medicine

DiaMedica Therapeutics Inc.

DMAC · Pharmaceutical Preparations

Modular Medical, Inc.

MODD · Surgical & Medical Instruments & Apparatus

MIMEDX GROUP, INC.

MDXG · Surgical & Medical Instruments & Apparatus

CAPRICOR THERAPEUTICS, INC.

CAPR · Pharmaceutical Preparations

: 11/08/2026